ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,347,513 | -42.6% | 161,798 | -23.8% | 0.00% | -25.0% |
| Q2 2023 | $7,571,295 | -15.4% | 212,319 | -39.8% | 0.00% | -33.3% |
| Q1 2023 | $8,953,703 | -5.4% | 352,508 | +51.1% | 0.01% | -25.0% |
| Q4 2022 | $9,464,271 | +5.0% | 233,340 | -14.4% | 0.01% | +14.3% |
| Q3 2022 | $9,015,000 | +24.8% | 272,751 | +33.0% | 0.01% | +16.7% |
| Q2 2022 | $7,221,000 | +299.6% | 205,120 | +422.2% | 0.01% | +500.0% |
| Q1 2022 | $1,807,000 | -72.8% | 39,277 | -60.7% | 0.00% | -75.0% |
| Q4 2021 | $6,633,000 | +25.7% | 100,042 | +18.4% | 0.00% | +33.3% |
| Q3 2021 | $5,275,000 | -39.1% | 84,488 | -19.2% | 0.00% | -40.0% |
| Q2 2021 | $8,664,000 | +33.5% | 104,603 | +6.9% | 0.01% | +25.0% |
| Q1 2021 | $6,490,000 | -73.7% | 97,871 | -69.6% | 0.00% | -73.3% |
| Q4 2020 | $24,687,000 | +163.9% | 321,744 | +48.1% | 0.02% | +150.0% |
| Q3 2020 | $9,355,000 | -5.6% | 217,237 | -5.3% | 0.01% | -25.0% |
| Q2 2020 | $9,909,000 | +62.3% | 229,428 | +8.1% | 0.01% | +60.0% |
| Q1 2020 | $6,107,000 | -33.1% | 212,237 | +47.5% | 0.01% | -28.6% |
| Q4 2019 | $9,126,000 | +69.4% | 143,867 | -24.7% | 0.01% | +75.0% |
| Q3 2019 | $5,387,000 | -33.4% | 191,123 | -37.4% | 0.00% | -42.9% |
| Q2 2019 | $8,090,000 | +140.5% | 305,261 | +66.5% | 0.01% | +75.0% |
| Q1 2019 | $3,364,000 | -64.5% | 183,338 | -76.0% | 0.00% | -55.6% |
| Q4 2018 | $9,474,000 | +54.6% | 762,801 | +138.5% | 0.01% | +50.0% |
| Q3 2018 | $6,130,000 | +140.2% | 319,828 | +70.5% | 0.01% | +200.0% |
| Q2 2018 | $2,552,000 | +134.1% | 187,600 | +24.0% | 0.00% | +100.0% |
| Q1 2018 | $1,090,000 | +958.3% | 151,264 | +441.0% | 0.00% | – |
| Q4 2017 | $103,000 | -31.3% | 27,961 | -19.2% | 0.00% | – |
| Q3 2017 | $150,000 | +733.3% | 34,587 | +218.9% | 0.00% | – |
| Q2 2017 | $18,000 | -65.4% | 10,846 | -61.7% | 0.00% | – |
| Q1 2017 | $52,000 | -66.0% | 28,329 | -71.1% | 0.00% | – |
| Q4 2016 | $153,000 | -31.4% | 98,063 | +223.6% | 0.00% | – |
| Q3 2016 | $223,000 | +374.5% | 30,300 | +250.1% | 0.00% | – |
| Q2 2016 | $47,000 | – | 8,655 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |